论文部分内容阅读
目的评估血小板糖蛋白GPⅡb/Ⅲa受体拮抗剂盐酸替罗非班对ST段抬高型性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)时防治无复流现象的作用。方法96例STEMI患者随机分为盐酸替罗非班组和对照组,观察两组P术后TIMI血流级别、24 h肌钙蛋白T水平、24 h及30 d复合心血管终点事件发生率及出血情况。结果替罗非班组和对照组PCI术后TIMI 3级血流发生率分别为94.2%和83.1%,TIMI 0～2级血流发生率分别为5.8%和15.9%;两组比较差异有统计学意义(P<0.05)。替罗非班组24 h肌钙蛋白T(CTnT)水平较对照组明显降低(P<0.05),替罗非班组较对照组主要复合终点心血管事件发生率有一定降低(P<0.05)。两组均无严重出血事件发生。结论盐酸替罗非班能明显降低急性心肌梗死直接PCI术后无复流现象的发生,并改善无复流现象程度。
Objective To evaluate the effect of platelet glycoprotein GPⅡb / Ⅲa receptor antagonist tirofiban on the prevention and treatment of no-reflow in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Methods Ninety-six patients with STEMI were randomly divided into two groups: the tirofiban hydrochloride group and the control group. The TIMI flow grade, 24 h Troponin T level, 24 h and 30 d composite cardiovascular end point events and bleeding Happening. Results Tirofiban group and control group TIMI grade 3 blood flow rate after PCI was 94.2% and 83.1%, TIMI grade 0 to 2 blood flow rates were 5.8% and 15.9%; two groups were statistically significant differences Significance (P <0.05). Tirofiban group 24 h Troponin T (CTnT) levels were significantly lower than the control group (P <0.05), tirofiban group than the control group main composite end point of the incidence of cardiovascular events have decreased (P <0.05). No severe bleeding occurred in either group. Conclusion Tirofiban hydrochloride can significantly reduce the incidence of no-reflow after PCI and improve the degree of no-reflow phenomenon in patients with acute myocardial infarction.